The efficacy of the anti-B7-H3 antibody enoblituzumab was evaluated in a phase I study in combination with pembrolizumab in PD-L1-naïve, relapsed, metastatic HNSCC after platinum treatment. This evidence concerns the gene CD274 and head and neck squamous cell carcinoma.